Clinical Trial Update: A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating darbepoetin alfa for the treatment of anemia in subjects with non-myeloid malignancy has completed. The trial was sponsored by Amgen.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: Anemia | Phase 3 | Status: COMPLETED